Document is current
Any future updates will be listed below
-
Authors
Nakasone, Hideki https://orcid.org/0000-0001-5812-9315
Kusuda, Machiko
Terasako-Saito, Kiriko
Kawamura, Koji
Akahoshi, Yu https://orcid.org/0000-0001-6825-9340
Kawamura, Masakatsu
Takeshita, Junko
Kawamura, Shunto
Yoshino, Nozomu
Yoshimura, Kazuki
Misaki, Yukiko
Gomyo, Ayumi
Kameda, Kazuaki
Tamaki, Masaharu
Tanihara, Aki
Kimura, Shun-ichi
Kako, Shinichi
Kanda, Yoshinobu https://orcid.org/0000-0002-4866-9307
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP17fm0208015, JP20ck0106479h)
- License Information
-
More Information
Article History
Received: 16 November 2020
Accepted: 21 September 2021
First Online: 11 October 2021
Competing interests
: H.N. has received honoraria from Takeda Pharmaceutical, Otsuka Pharmaceutical, Bristol-Myers Squibb, Celgene, Pfizer, Novartis, Janssen Pharmaceutical, Eisai, Chugai Pharmaceutical, and Nippon Shinyaku. S. Kimura has received honoraria from Asahi Kasei, Sumitomo Dainippon Pharma, MSD, Astellas, Pfizer, Kyowa Kirin, Chugai Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Celgene, Ono Pharmaceutical Co., Ltd., Eisai Co., Ltd., and Nippon Kayaku. S. Kako has received honoraria from Novartis, and Bristol-Myers Squibb. Y.K. has received honoraria from MSD, Astellas, Sumitomo Dainippon Pharma, Chugai Pharmaceutical, Pfizer, Novartis, Otsuka Pharmaceutical, Eisai, and Janssen Pharmaceutical Kyowa Kirin, Takeda Pharmaceutical, Ono Pharmaceutical, Shionogi & Co., Bristol-Myers Squibb, Celgene, Mochida, Alexion, and Takara-Bio, and research grants from Celgene, Astellas, Chugai Pharmaceutical, Kyowa Kirin, Ono Pharmaceutical, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, Eisai, Shionogi & Co., Otsuka Pharmaceutical, Nippon-Shinyaku, Taiho, Pfizer, MSD, Asahi-Kasei Corporation, Sanofi, Novartis, Taisho-Toyama, CSL Behring, and Tanabe-Mitsubishi. The other authors report no potential competing conflicts of interest.
